Catalyst · trial start
Pfizer expects to advance danuglipron once-daily formulation into phase 3 in 2025.
Expected: Jan 1, 2025 – Jun 30, 2025
Catalyst details
- Type
- trial start
- Status
- pending
- Date precision
- window
- Confidence
- company guidance
- Asset
- Danuglipron
- Company
- Pfizer
Dependencies
- trial-07
Source wording
“Pfizer expects to advance danuglipron once-daily formulation into phase 3 in 2025.”
Sources
- company-releaseprimary record
Pfizer provides update on phase 2 oral GLP-1 program: discontinuation of lotiglipron
Pfizer Inc. · Pfizer Press Release · Jun 26, 2023